US FDA May Reconsider RMAT Requests If Resubmitted With Sufficient Clinical Data
Rejection of an RMAT request does not mean necessarily mean the FDA won't grant one. The agency will accept new clinical data to support the application through a “reconsideration” process, industry official says.
You may also be interested in...
Final guidance notes that preliminary clinical evidence may come from studies conducted outside the US, says historical controls may be considered in clinical trial designs.
FDA denied breakthrough therapy request until AbbVie and Roche demonstrated substantial improvement over available treatment in 17p deletion chronic lymphocytic leukemia, review documents show.
In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.